Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeAndrea Rinaldi, Francesco Bertoni, Francesco Forconi et al.|Blood|2010Cited by 189
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOPAlexandar Tzankov, Ken H. Young, Zijun Y. Xu‐Monette et al.|Modern Pathology|2013Cited by 129
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10Eva Kimby, Emanuele Zucca, Giovanni Martinelli et al.|Blood|2014Cited by 18
Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone LymphomasAndrea Rinaldi, Francesco Bertoni, Paola M. V. Rancoita et al.|Blood|2008Cited by 5